TAVI Live Case: Commissural Alignment with ACURATE neo2

Dr Andreas Rück is the head of the Transcatheter Aortic Valve Implantation (TAVI) program at Karolinska University Hospital – Stockholm, Sweden and the chairman of the Swedish Percutaneous Valve Registry (a registry within the Swedish Heart Registries SWEDEHEART). He is member of the steering group of SWEDEHEART and of the Working group for PCI and Valve Interventions within the Swedish Society of Cardiology. His clinical specialties include PCI and percutaneous valve implantation.

Dr. Christopher U. Meduri is an interventional cardiologist at Karolinska University Hospital – Stockholm, Sweden. He is board certified in internal medicine and cardiology and a member of the American College of Cardiology. Dr. Meduri has special interest in optimizing care of patients with valvular heart disease. He has received multiple educational grants to improve care of patients with aortic valve disorders and developed a mobile application, Post-TAVR Optimization, to assist centers performing TAVR in post-procedure management.

A deputy director, dpt. of cardiac surgery at Heart Center Leipzig, Germany. Features in 7 videos on Wondr Medical. David Holzhey generally speaks on Transcatheter Aortic Valve Implantation (TAVR / TAVI), Acute Coronary Syndromes (ACS), Cardiac Valves, Aortic Valve Pathology, and Aortic Stenosis (AS).

Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).

Dr. Mohammed Nejjari is a specialist in valvular heart disease. He is the head of the department of interventional cardiology at Centre Cardiologique du Nord in Saint-Denis, France.

Dr. Nawzad Saleh is an associate professor, senior consultant, interventional cardiologist and head of Percutaneous Valve Intervention at Karolinska University Hospital – Stockholm, Sweden.